Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

Boehringer Ingelheim’s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis

Fineline Cube Oct 23, 2025

Boehringer Ingelheim announced that its oral selective phosphodiesterase‑4B (PDE4B) inhibitor Nerandomilast (JASCAYD®) has received formal...

Company Deals

Fosun Pharma & Helsinn Partner to Produce Fosnetupitant for Akynzeo in China

Fineline Cube Oct 23, 2025

Fosun Pharma (SHA: 600196, HKG: 2196) and the Helsinn Healthcare SA announced a strategic cooperation...

Company Drug

PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study

Fineline Cube Oct 23, 2025

Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase III EV‑303 (KEYNOTE‑905) trial...

Company Drug

AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA

Fineline Cube Oct 23, 2025

AbbVie (NYSE: ABBV) announced positive topline data from its Phase IIIb/IV head‑to‑head trial, SELECT‑SWITCH, comparing upadacitinib...

Company Drug

Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC

Fineline Cube Oct 23, 2025

China‑based Harbour BioMed (HKG: 2142) announced positive results from its multicenter, open‑label Phase II trial (NCT 05167071)...

Policy / Regulatory

VBP 11th Finalizes 389 Participants, 3.7 Billion Doses Set for Centralized Procurement

Fineline Cube Oct 23, 2025

The Office of the National Drug Joint Procurement (ONDJP) published the conclusive enterprise roster for...

Company

Roche Reports 7 % YoY Revenue Growth Through Q3 2025, Raises Full‑Year Guidance

Fineline Cube Oct 23, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7 % year‑on‑year (YoY)...

Company

Novo Nordisk Board Shake‑Up: Chairman Helge Lund and Six Members Step Down After Disagreement With Foundation

Fineline Cube Oct 22, 2025

Novo Nordisk A/S (NYSE: NVO) announced today that Chairman Helge Lund and six other board...

Company Deals

Innovent and Takeda Forge $11.4 B Partnership on IBI363, IBI343 & IBI3001 ADC Therapies

Fineline Cube Oct 22, 2025

Innovent Biologics, Inc. (HKG: 1801) today announced a landmark global strategic collaboration with Takeda Pharmaceutical...

Company

Galapagos Announces Exit from Cell‑Therapy Business After Strategic Review

Fineline Cube Oct 22, 2025

Galapagos NV (FRA: GXE) today disclosed that it has decided to wind down its cell‑therapy...

Company Drug

GFH375 Enters Phase Ib/II at Peking University: GenFleet Targets KRAS G12D

Fineline Cube Oct 22, 2025

GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled...

Company Deals

Rani Therapeutics and Chugai Forge $1.085 Billion Collaboration Deal for Innovative Oral Therapeutic

Fineline Cube Oct 22, 2025

Rani Therapeutics Holdings, Inc. today announced a comprehensive Collaboration and License Agreement with Japan’s Chugai...

Company Drug

BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025

Fineline Cube Oct 22, 2025

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase III BRIGHT‑3...

Company Drug

Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors

Fineline Cube Oct 22, 2025

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the National Medical Products Administration (NMPA)...

Company Drug

Huadong Medicine Secures FDA Approval for DR10624, First‑In‑Class Trispecific Agonist for Severe Hypertriglyceridemia

Fineline Cube Oct 22, 2025

Huadong Medicine (SHE: 000963) announced that the Investigational New Drug (IND) application for DR10624 Injection,...

Company Drug

AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY‑Breast11 at ESMO 2025

Fineline Cube Oct 22, 2025

AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase III DESTINY‑Breast11 results at...

Company Drug

Indetek Laboratory Secures NMPA Approval for IDT‑001 Gel, a Novel Film‑Forming Therapy for SSTIs

Fineline Cube Oct 22, 2025

Indetek Laboratory announced that the National Medical Products Administration (NMPA) has formally accepted the New...

Company Drug

Fosun‑Henlius Announces 26.8‑Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC

Fineline Cube Oct 22, 2025

Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase III...

Company Drug

Novartis Announces Five‑Year NATALEE Results for Kisqali in HR+/HER2‑ Early Breast Cancer

Fineline Cube Oct 22, 2025

Novartis (NYSE: NVS) presented the five‑year interim analysis of its pivotal Phase III NATALEE study at...

Company Drug

Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type 2 Diabetes

Fineline Cube Oct 21, 2025

Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted...

Posts pagination

1 … 133 134 135 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.